Literature DB >> 22297599

Human neutrophil peptides 1-3 as gastric cancer tissue markers measured by MALDI-imaging mass spectrometry: implications for infiltrated neutrophils as a tumor target.

Chun-Chia Cheng1, Jungshan Chang, Ling-Yun Chen, Ai-Sheng Ho, Ker-Jer Huang, Shui-Cheng Lee, Fu-Der Mai, Chun-Chao Chang.   

Abstract

OBJECTIVE: Human neutrophil peptides (HNPs) -1, -2 and -3 are significantly upregulated and were reported as biomarkers in gastric cancer (GC). However, the tissue location and function of HNPs 1-3 are still unclear in GC, and the spatial distribution of the triad needs to be disclosed. The aims of this study were to investigate the distribution and relationships among HNPs-1, -2 and -3, and assess whether infiltrated neutrophils accumulate in gastric tumor.
METHODS: In this study, paired samples (n=33) of the GC tissues and adjacent normal tissues from the same patients were obtained from surgery. Expression of HNPs 1-3 were detected by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). The distributions of the HNPs 1-3 in GC tissues were investigated. After verification of HNPs-1 by immunohistochemistry, infiltrated neutrophils were also detected. Then, an in vitro assay was used to observe the binding capacity and measure the cytotoxic effect of HNPs-1 against AGS cells.
RESULTS: Comparing to neighboring normal tissue, expressional level of HNPs 1-3 were significantly higher and their distributions overlapped in cancerous tissues of GC patients with high abundance in the lamina propria, whereas HNPs-1 was identified as the highest major peak. Moreover, HNPs-1, -2 and -3 correlated with each other. Besides, we also observed that increased infiltrated neutrophils accumulating in GC tissues, indicating that a strong positive correlation between HNPs 1-3 and infiltrated neutrophils. In addition, the further investigated demonstrated that the major peptide, HNPs-1, was statistically increased with the advance of tumor development from the early to advanced stage of GC (p< 0.05). Moreover, we also noticed that HNPs-1 with a great binding capacity to GC AGS cells in vitro can inhibit tumor cell growth.
CONCLUSIONS: Our results suggest that neutrophil secreted peptides, HNPs 1-3, increased in the GC tissues and could be used as potential biomarkers detected using MALDI-TOF MS, implying that elevated neutrophils may be used as a tumor target for tumor treatment. The binding capacity of HNPs-1 with GC cells implies that tracking molecules conjugated with HNPs-1 could be applied as a specific probe for GC diagnoses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22297599      PMCID: PMC3826590          DOI: 10.3233/DMA-2012-0857

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  4 in total

1.  Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers.

Authors:  Ai-Sheng Ho; Chien-Hsin Chen; Chun-Chia Cheng; Chia-Chi Wang; Hua-Ching Lin; Tsai-Yueh Luo; Gi-Shih Lien; Jungshan Chang
Journal:  Oncotarget       Date:  2014-01-30

2.  Interactive Visual Exploration of 3D Mass Spectrometry Imaging Data Using Hierarchical Stochastic Neighbor Embedding Reveals Spatiomolecular Structures at Full Data Resolution.

Authors:  Walid M Abdelmoula; Nicola Pezzotti; Thomas Hölt; Jouke Dijkstra; Anna Vilanova; Liam A McDonnell; Boudewijn P F Lelieveldt
Journal:  J Proteome Res       Date:  2018-02-15       Impact factor: 4.466

3.  Investigation Of Small Molecular Substances As Potential Biomarkers For Discrimination Of Gastric Tumor.

Authors:  Jianyong Zhang; Qingjun Gao; Xue Luo; Wenxiong Zhang; Nanpeng Wang; Yiping Wei
Journal:  Onco Targets Ther       Date:  2019-10-17       Impact factor: 4.147

Review 4.  Matrix-Assisted Laser Desorption/Ionisation Mass Spectrometry Imaging in the Study of Gastric Cancer: A Mini Review.

Authors:  Andrew Smith; Isabella Piga; Manuel Galli; Martina Stella; Vanna Denti; Marina Del Puppo; Fulvio Magni
Journal:  Int J Mol Sci       Date:  2017-12-01       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.